Updated phase I data of AFM13: A bispecific tandem antibody (TandAb) in relapsed/refractory (R/R) Hodgkin lymphoma (HL).

Achim Rothe,Max S. Topp,Dennis A. Eichenauer,Bastian von Tresckow,Horst-Dieter Hummel,Miroslav Ravic,Jens-Peter Marschner,Andreas Engert

Updated phase I data of AFM13: A bispecific tandem antibody (TandAb) in relapsed/refractory (R/R) Hodgkin lymphoma (HL).

2014

Achim Rothe
Max S. Topp
Dennis A. Eichenauer
Bastian von Tresckow
Horst-Dieter Hummel
Miroslav Ravic
Jens-Peter Marschner
Andreas Engert

3025^ Background: AFM13 is a bispecific anti-CD30, anti-CD16A antibody construct which recruits NK cells for targeted lysis of CD30+ tumor cells. HL cells are characterized by CD30 positivity and r...

Keywords:

Antibody
Lymphoma
Pathology
Cancer research
Medicine
hodgkin lymphoma
CD30
relapsed refractory
tumor cells

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations